Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

Nature Clinical Practice Oncology volume 5, pages 374–375 (2008)Cite this article

A Corrigendum to this article was published on 01 August 2008

boxed-textDimopoulos M et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123–2132

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hideshima T et al. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585–598

    Article  CAS  Google Scholar 

  2. Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067

    Article  CAS  Google Scholar 

  3. Weber DM et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133–2142

    Article  CAS  Google Scholar 

  4. Palumbo A et al. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414–423

    Article  CAS  Google Scholar 

  5. Rajkumar SV et al. (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110: 74a

    Article  Google Scholar 

  6. Palumbo A et al. (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 25: 4459–4465

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chief of the Division of Hematologic Neoplasia and the Kraft Family Professor of Medicine at Harvard Medical School, NC Munshi is the Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and Associate Professor of Medicine at the Harvard Medical School and Attending Physician at the Boston VA Healthcare System. CS Mitsiades is an Instructor in Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. PG Richardson is the Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and Associate Professor of Medicine at the Harvard Medical School. KC Anderson is the Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, Boston, MA, USA.,

    Nikhil C Munshi, Constantine Mitsiades, Paul G Richardson & Kenneth C Anderson

Authors
  1. Nikhil C Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constantine Mitsiades
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul G Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenneth C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikhil C Munshi.

Ethics declarations

Competing interests

P Richardson is on the speaker's bureau of Celgene and Millenium. K Anderson and N Munshi are Consultants, on the speaker's bureau and receive grant/research support from Celgene and Millenium. C Mitsiades declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Munshi, N., Mitsiades, C., Richardson, P. et al. Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Rev Clin Oncol 5, 374–375 (2008). https://doi.org/10.1038/ncponc1151

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1151

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing